ALISSA MACIAS: Open Payments
NPI 1952658445 · SAN MARCOS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$922 in 38 payments from 12 companies in 2025. Trend: 2023 $374 · 2024 $765 · 2025 $922
Food & beverage: $922
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 12 | $220 |
| Braeburn Inc. | 3 | $166 |
| Madrigal Pharmaceuticals | 4 | $101 |
| Lilly USA, LLC | 4 | $78 |
| Novo Nordisk Inc | 3 | $75 |
| ABBVIE INC. | 3 | $75 |
| Xeris Pharmaceuticals, Inc. | 3 | $57 |
| Edwards Lifesciences Corporation | 1 | $43 |
| SCILEX PHARMACEUTICALS INC. | 2 | $40 |
| GlaxoSmithKline, LLC. | 1 | $29 |
Products named: BRIXADI, REZDIFFRA, MOUNJARO, SAPIEN 3 Ultra RESILIA, ELYXYB - CELECOXIB, GVOKE HYPOPEN, UBRELVY, SHINGRIX.
Industry payments across CA — which companies pay providers there.
